{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:51:58Z","timestamp":1791323518202,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacl.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:37:22Z","timestamp":1787787442000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-6997","authenticated-orcid":false,"given":"Pamela L.","family":"Alebna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7934-538X","authenticated-orcid":false,"given":"Matthew K.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2185-5011","authenticated-orcid":false,"given":"Kayla","family":"Harley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yip Han","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas WS","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-9315","authenticated-orcid":false,"given":"Fadi N.","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-5551","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2026.08.005_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.005_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033488","article-title":"Independent relationship of lipoprotein(a) and carotid atherosclerosis with long-term risk of cardiovascular disease","volume":"13","author":"Qi","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jacl.2026.08.005_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacl.2026.08.005_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"JACC"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.005_bib5","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.jacl.2026.08.005_bib6","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.jacl.2026.08.005_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.005_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.005_bib9","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"10002","key":"10.1016\/j.jacl.2026.08.005_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"10057","key":"10.1016\/j.jacl.2026.08.005_bib11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.005_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.005_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2022.12.001","article-title":"Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects","volume":"17","author":"Karwatowska\u2011Prokopczuk","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2026.08.005_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.005_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.005_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.005_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"issue":"20","key":"10.1016\/j.jacl.2026.08.005_bib18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacl.2026.08.005_bib19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jacl.2026.08.005_bib20","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2026.08.005_bib21","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.08.005_bib22","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacl.2026.08.005_bib23","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2026.08.005_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25675","article-title":"Statins and LDL-C in secondary prevention\u2014so much progress, so far to go","volume":"3","author":"Banach","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.005_bib25","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.08.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.005_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jacl.2026.08.005_bib28","unstructured":"Eli Lilly and CompanyA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a) 2026 clinicaltrials.gov,.Accessed February 15, 2026https:\/\/clinicaltrials.gov\/study\/NCT06292013."},{"key":"10.1016\/j.jacl.2026.08.005_bib29","unstructured":"Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event. clinicaltrials.gov; 2026. Accessed February 15, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07157774."},{"issue":"3","key":"10.1016\/j.jacl.2026.08.005_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.005_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ymthe.2024.01.008","article-title":"Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.jacl.2026.08.005_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.crbiot.2023.100150","article-title":"An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: current landscape","volume":"6","author":"Chatterjee","year":"2023","journal-title":"Curr Res Biotechnol"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.005_bib33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bcp.12961","article-title":"Injection site reactions after subcutaneous oligonucleotide therapy","volume":"82","author":"van Meer","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.005_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol\u2013mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.005_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"for the Lp(a)-GWAS-Consortium. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2026.08.005_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2026.08.005_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of cardiovascular events and lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2026.08.005_bib38","unstructured":"Amgen A double-blind, randomized, placebo-controlled, multicenter study assessing Olpasiran use to prevent first major cardiovascular events in participants with elevated lipoprotein(a) 2026 clinicaltrials.gov,.Accessed February 22, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07136012."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:14:40Z","timestamp":1791321280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S1933287426004800"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}